New hope for rare blood cancer: targeted drug plus chemotherapy under study

NCT ID NCT06630091

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy (CHOP) can better control newly diagnosed peripheral T cell lymphoma, a rare and aggressive blood cancer. About 30 adults will receive the combination, and researchers will monitor side effects and how well the cancer responds. The study is currently recruiting at MD Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: golidocitinib (a targeted drug) combined with standard chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone)
What this could lead to: If successful, this could offer a new first-line treatment option for peripheral T cell lymphoma, potentially improving disease control and survival.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply broadly. The combination therapy may cause significant side effects, and it is not yet known if it works better than standard treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioimmunoblastic T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.